{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T22:43:19Z","timestamp":1792190599912,"version":"4.4.0"},"reference-count":24,"publisher":"American Society of Tropical Medicine and Hygiene","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,2,7]]},"abstract":"<jats:p>\n                    Serious neurological adverse events have been reported from large scale community-based ivermectin treatment campaigns against\n                    <jats:italic>Onchocerciasis volvulus<\/jats:italic>\n                    in Africa. The mechanism of these events has been debated in the literature, largely focusing on the role of concomitant infection with\n                    <jats:italic>Loa loa<\/jats:italic>\n                    versus the presence of mdr-1 gene variants in humans allowing ivermectin penetration into the central nervous system. A case series of serious neurological adverse events occurring with the use of ivermectin outside of the onchocerciasis indication has been identified in VigiBase, an international database of suspected adverse drug reactions. Forty-eight cases have been reported from multiple countries in which ivermectin has been prescribed for multiple indications; clinical review excluded 20 cases with more probable explanations or other exclusion criteria. Within the remaining 28 cases, there is supportive evidence for a causative role of ivermectin including presence of the drug in brain tissue in one case and recurrence of symptoms on repeated exposure in three cases. This series suggests that serious neurological adverse events observed with the use of ivermectin in the treatment of onchocerciasis may not be entirely explained by concomitant high burden loiasis infections. By comparison with the extensive post marketing experience with ivermectin in the successful treatment of parasitic infections, the number of reported cases suggests that such events are likely rare. However, elucidation of individual-level risk factors could contribute to therapeutic decisions that can minimize harms. Further investigation into the potential for drug\u2013drug interactions and explorations of polymorphisms in the mdr-1 gene are recommended.\n                  <\/jats:p>","DOI":"10.4269\/ajtmh.17-0042","type":"journal-article","created":{"date-parts":[[2017,12,5]],"date-time":"2017-12-05T02:00:35Z","timestamp":1512439235000},"page":"382-388","source":"Crossref","is-referenced-by-count":131,"title":["Serious Neurological Adverse Events after Ivermectin\u2014Do They Occur beyond the Indication of Onchocerciasis?"],"prefix":"10.4269","volume":"98","author":[{"given":"Rebecca E.","family":"Chandler","sequence":"first","affiliation":[{"name":"Uppsala Monitoring Centre, Uppsala, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2795","reference":[{"key":"b1","series-title":"Stromectol (ivermectin) Package Insert","author":"Dohme","year":"2010"},{"key":"b2","series-title":"Prescrire Int","first-page":"137","article-title":"Ivermectin: new indication. Oral treatment of scabies: simple and effective","volume":"11","author":"No authors listed","year":"2002"},{"key":"b3","series-title":"Invermectin (Stromectol) for Typical and Crusted Scabies","author":"NPSMedicineWise","year":"2014"},{"key":"b4","series-title":"Am Fam Physician","first-page":"1089","article-title":"Ivermectin use in scabies","volume":"68","author":"Fawcett","year":"2003"},{"key":"b5","series-title":"N Engl J Med","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1056\/NEJMoa0905471","article-title":"Oral ivermectin versus malathion lotion for difficult-to-treat head lice","volume":"362","author":"Chosidow","year":"2010"},{"key":"b6","series-title":"Proc Natl Acad Sci USA","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1073\/pnas.86.2.695","article-title":"Multi-drug resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites","volume":"86","author":"Cordon-Cardo","year":"1989"},{"key":"b7","series-title":"Ann Emerg Med","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/S0196-0644(99)70271-4","article-title":"Agricultural avermectins: an uncommon but potentially fatal cause of pesticide poisoning","volume":"34","author":"Chung","year":"1999"},{"key":"b8","series-title":"Curr Pharm Biotechnol","doi-asserted-by":"publisher","first-page":"999","DOI":"10.2174\/138920112800399059","article-title":"Acute human toxicity of macrocyclic lactones","volume":"13","author":"Yang","year":"2012"},{"key":"b9","series-title":"Filaria J","first-page":"S4","article-title":"Clinical picture, epidemiology, and outcome of Loa-associated serious adverse events related to mass ivermectin treatment of onchocerciasis in Cameroon","volume":"2","author":"Boussinesq","year":"2003"},{"key":"b10","series-title":"Lancet","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/S0140-6736(96)11094-1","article-title":"Serious reactions after mass treatment of onchocerciasis with ivermectin in an area endemic for Loa loa infections","volume":"350","author":"Gardon","year":"1997"},{"key":"b11","series-title":"Trends Parasitol","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1016\/j.pt.2005.08.014","article-title":"Ivermectin 20 years on: maturation of a wonder drug","volume":"21","author":"Geary","year":"2005"},{"key":"b12","series-title":"Trends Parasitol","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/j.pt.2006.04.006","article-title":"What are the mechanisms associated with post-ivermectin serious adverse events?","volume":"22","author":"Boussinesq","year":"2006"},{"key":"b13","series-title":"Drug Inf J","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1177\/009286150804200501","article-title":"Vigibase, the WHO global ICSR database system: basic facts","volume":"42","author":"Lindquist","year":"2008"},{"key":"b14","series-title":"Ich Harmonised Tripartite Guideline Post-Approval Safety Data Management: Definitions and Standards for Expedited Reporting E2d","author":"ICH Expert Working Group","year":"2003"},{"key":"b15","series-title":"Clin Infect Dis","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1093\/cid\/cit656","article-title":"Persistent coma in Strongyloides hyperinfection syndrome associated with persistently increased ivermectin levels","volume":"58","author":"van Westerloo","year":"2014"},{"key":"b16","series-title":"Cell","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/0092-8674(94)90212-7","article-title":"Disruption of the mouse mdr1a-p-glycopretin gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs","volume":"77","author":"Schinkel","year":"1994"},{"key":"b17","series-title":"Pharmacogenetics","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1097\/00008571-200111000-00012","article-title":"Ivermectin sensitivity in collies is associated with a deletion mutation of the mdr1 gene","volume":"11","author":"Mealey","year":"2001"},{"key":"b18","series-title":"Lancet","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1016\/S0140-6736(05)63020-6","article-title":"Deaths associated with ivermectin treatment of scabies","volume":"349","author":"Barkwell","year":"1997"},{"key":"b19","series-title":"Lancet","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/S0140-6736(05)62377-X","article-title":"Deaths associated with ivermectin for scabies","volume":"350","author":"Coyne","year":"1997"},{"key":"b20","series-title":"J Clin Pharmacol","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1177\/009127002237994","article-title":"Safety, tolerability, and pharmacokinteics of escalating high doses of ivermectin in healthy study subjects","volume":"42","author":"Guzzo","year":"2002"},{"key":"b21","series-title":"Int J Pharm","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.ijpharm.2002.12.002","article-title":"Unmasking the dynamic interplay between efflux transporters and metabolic enzymes","volume":"277","author":"Benet","year":"2004"},{"key":"b22","series-title":"BMC Pharmacol Toxicol","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s40360-017-0129-6","article-title":"Drug-transporter mediated interactions between anthelminthic and antiretroviral drugs across the Caco-2 cell monolayers","volume":"18","author":"Kigen","year":"2017"},{"key":"b23","series-title":"Arch Toxicol","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1007\/s00204-007-0193-6","article-title":"Potential impact of ABCB1 (p-glycoprotein) polymorphisms on avermectin toxicity in humans","volume":"81","author":"Macdonald","year":"2007"},{"key":"b24","series-title":"Am J Trop Med Hyg","doi-asserted-by":"publisher","first-page":"28","DOI":"10.4269\/ajtmh.2010.09-0734","article-title":"Analysis of the mdr-1 gene in patients co-infected with Onchocerca volvulus and Loa loa who experienced a post-ivermectin serious adverse event","volume":"83","author":"Bourguinat","year":"2010"}],"container-title":["The American Journal of Tropical Medicine and Hygiene"],"original-title":[],"link":[{"URL":"https:\/\/www.ajtmh.org\/view\/journals\/tpmd\/98\/2\/article-p382.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.ajtmh.org\/downloadpdf\/journals\/tpmd\/98\/2\/article-p382.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/www.ajtmh.org\/downloadpdf\/journals\/tpmd\/98\/2\/article-p382.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,31]],"date-time":"2024-07-31T19:02:41Z","timestamp":1722452561000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ajtmh.org\/view\/journals\/tpmd\/98\/2\/article-p382.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2,7]]},"references-count":24,"journal-issue":{"issue":"2"},"URL":"https:\/\/doi.org\/10.4269\/ajtmh.17-0042","relation":{},"ISSN":["0002-9637","1476-1645"],"issn-type":[{"value":"0002-9637","type":"print"},{"value":"1476-1645","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,2,7]]}}}